Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409108 | 0.84 | AR (0.74) | AR | |
| SCHEMBL12180588 | 0.82 | AR (0.43) | AR | |
| SCHEMBL20455595 | 0.80 | AR (0.42) | AR | |
| SCHEMBL29890778 | 0.80 | AR (0.42) | AR | |
| SCHEMBL325632 | 0.78 | AR (0.50) | ARSLC22A12 | |
| SCHEMBL29421468 | 0.78 | AR (0.50) | ARSLC22A12 | |
| SCHEMBL5203682 | 0.78 | KIF11 (0.53) | ARSLC22A12 | |
| SCHEMBL1996176 | 0.78 | AR (0.53) | ARSLC22A12 | |
| SCHEMBL22722421 | 0.76 | TRPV4 (0.52) | ARSLC22A12 | |
| SCHEMBL663706 | 0.76 | AR (0.43) | ARSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025224085-A1 | COMPOUNDS CAPABLE OF ACTING ON S1R AS WELL AS ON SEH AND USES THEREOF | UNIVERSITAT DE BARCELONA (ES) | 2025-10-30 | — | — | WO | disclosed |
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-3471729-B1 | ISOXAZOLMETHYLTHIO-, THIENYLMETHYLTHIO- AND THIAZOMETHYLTHIO-DERIVATIVES FOR USE IN THE TREATMENT OF CANCER; VIRAL INFECTIONS; THROMBOTIC EVENTS OR PLATELET AGGREGATION | UNIV RUTGERS (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-3466953-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2021-02-03 | — | — | EP | disclosed |
| US-10851096-B2 | Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200235304-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2020-07-23 | — | — | US | disclosed |
| US-20200121677-A1 | SUBSTITUTED 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (US) | 2020-04-23 | — | — | US | disclosed |
| US-20190127361-A1 | Therapeutic Compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-05-02 | — | — | US | disclosed |
| WO-2019078620-A1 | NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME | 주식회사 엘지화학 | 2019-04-25 | — | — | WO | disclosed |
| US-20190055257-A1 | SUBSTITUTED 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-21 | — | — | US | disclosed |
| US-20110312911-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME CORP. | 2011-12-22 | — | — | US | disclosed |
| EP-1966202-B1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORP (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2366699-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-09-21 | — | — | EP | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| CN-101717350-A | Method for synthesizing aryl cyanide in aqueous solution | NANJING UNIVERSITY OF TECHNOLOGY | 2010-06-02 | — | — | CN | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| CN-100528876-C | Pyrrazolo-pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | CN | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
| CN-1964973-A | Pyrrazolo-pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2007-05-16 | — | — | CN | disclosed |
| CN-1134936-A | Herbicidal (1,2,4) thiadiazoles | AMERICAN CYANAMID CO (US) | 1996-11-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127361-A1 | Therapeutic Compounds | SDHA, SLC10A1, SERPINC1 | AR 3732/4885SLC22A12 839/4885 |
| US-20190055257-A1 | SUBSTITUTED 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM5, GRM1 | AR 1534/4885SLC22A12 967/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | AR 2489/4885SLC22A12 4617/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | AR 3947/4885SLC22A12 4603/4885 |
| US-20200121677-A1 | SUBSTITUTED 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM5, GRM1 | AR 1534/4885SLC22A12 967/4885 |
| US-10851096-B2 | Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents | SERPINC1, F12, RPL35 | AR 3666/4885SLC22A12 3821/4885 |
| US-20200235304-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | C1S, CBR3, CCNL2 | AR 292/4885SLC22A12 4289/4885 |
| US-20110312911-A1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | GCGR, GLP1R, GPR119 | AR 471/4885SLC22A12 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.